#ICYMI at #AACR20 we presented preclinical data from our two lead clinical-stage antibody therapies: SRF617 (targeting CD39) & SRF388 (targeting IL-27). Check out our poster presentations on our website & visit the trial pages on https://t.co/To2kvEJzKw: https://t.co/bDXiCtjV6I